Minimal change glomerular disease associated with solid neoplasms: a systematic review.
Cozzo D, Orlando F, Bruno M, Ogna A, Forni Ogna V.
J Nephrol. 2025 Mar;38(2):343-352. doi: 10.1007/s40620-024-02084-6. Epub 2024 Oct 1.
[Paraneoplastic autoimmune disorders].
Hirokawa M.
Gan To Kagaku Ryoho. 2010 Jun;37(6):980-3.
Onco-nephrology: glomerular diseases with cancer.
Cambier JF, Ronco P.
Clin J Am Soc Nephrol. 2012 Oct;7(10):1701-12. doi: 10.2215/CJN.03770412. Epub 2012 Aug 16.
Paraneoplastic glomerulopathies.
Norris SH.
Semin Nephrol. 1993 May;13(3):258-72.
Serum levels of tumor associated trypsin inhibitor (TATI) and glomerular filtration rate.
Tramonti G, Ferdeghini M, Donadio C, Annichiarico C, Norpoth M, Bianchi R, Bianchi C.
Ren Fail. 1998 Mar;20(2):295-302. doi: 10.3109/08860229809045114.
Membranous nephropathy-one morphologic pattern with different diseases.
Hoxha E, von Haxthausen F, Wiech T, Stahl RAK.
Pflugers Arch. 2017 Aug;469(7-8):989-996. doi: 10.1007/s00424-017-2000-4. Epub 2017 May 29.
Wilms tumor and the WT1 gene.
Lee SB, Haber DA.
Exp Cell Res. 2001 Mar 10;264(1):74-99. doi: 10.1006/excr.2000.5131.
Tumor marker elevations in chronic kidney disease: a retrospective study.
You L, Xu Z, Liu Q, Jin G, Wang C.
PeerJ. 2025 Apr 3;13:e19240. doi: 10.7717/peerj.19240. eCollection 2025.
Carcinoid tumor and the nephrotic syndrome: a novel association between neoplasia and glomerular disease.
Becker BN, Goldin G, Santos R, Glick A, Johnson DH, Breyer JA, Schulman GS.
South Med J. 1996 Feb;89(2):240-2. doi: 10.1097/00007611-199602000-00019.
[Glomerulonephritis in neoplastic disease].
Mazanowska O, Klinger M.
Pol Merkur Lekarski. 2005 Aug;19(110):211-4.
